Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Hepatocellular carcinoma.
|
Lancet
|
2012
|
18.09
|
2
|
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
|
Semin Liver Dis
|
2010
|
9.73
|
3
|
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
9.20
|
4
|
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.
|
Hepatology
|
2002
|
6.92
|
5
|
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.
|
Hepatology
|
2008
|
6.75
|
6
|
Lin28 promotes transformation and is associated with advanced human malignancies.
|
Nat Genet
|
2009
|
6.35
|
7
|
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
|
Lancet Oncol
|
2008
|
5.93
|
8
|
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
|
Mol Cancer Ther
|
2008
|
5.78
|
9
|
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
|
J Hepatol
|
2006
|
5.17
|
10
|
Resection of hepatocellular cancer ≤2 cm: results from two Western centers.
|
Hepatology
|
2013
|
5.05
|
11
|
Prognostic prediction and treatment strategy in hepatocellular carcinoma.
|
Hepatology
|
2002
|
4.83
|
12
|
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
|
Gastroenterology
|
2009
|
4.50
|
13
|
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
|
Cancer Res
|
2008
|
4.35
|
14
|
Pivotal role of mTOR signaling in hepatocellular carcinoma.
|
Gastroenterology
|
2008
|
4.03
|
15
|
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.
|
Hepatology
|
2007
|
3.85
|
16
|
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
|
Cancer Res
|
2009
|
3.77
|
17
|
Genomics and signaling pathways in hepatocellular carcinoma.
|
Semin Liver Dis
|
2007
|
3.75
|
18
|
CCR1 and CCR5 promote hepatic fibrosis in mice.
|
J Clin Invest
|
2009
|
3.62
|
19
|
Focus on hepatocellular carcinoma.
|
Cancer Cell
|
2004
|
3.49
|
20
|
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.
|
Nat Biotechnol
|
2009
|
3.44
|
21
|
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
|
J Hepatol
|
2012
|
3.04
|
22
|
Chemoembolization for hepatocellular carcinoma.
|
Gastroenterology
|
2004
|
2.89
|
23
|
Targeted therapies for hepatocellular carcinoma.
|
Gastroenterology
|
2011
|
2.85
|
24
|
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.
|
J Clin Invest
|
2009
|
2.79
|
25
|
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
|
Gastroenterology
|
2011
|
2.66
|
26
|
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
|
J Hepatol
|
2007
|
2.58
|
27
|
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.
|
Hepatology
|
2004
|
2.54
|
28
|
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
|
J Hepatol
|
2012
|
2.53
|
29
|
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
|
Semin Liver Dis
|
2010
|
2.46
|
30
|
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
|
J Hepatol
|
2009
|
2.42
|
31
|
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
|
Gastroenterology
|
2013
|
2.42
|
32
|
Gene-expression signature of vascular invasion in hepatocellular carcinoma.
|
J Hepatol
|
2011
|
2.39
|
33
|
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
|
Hepatology
|
2006
|
2.38
|
34
|
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
|
Cancer
|
2009
|
2.38
|
35
|
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.
|
Gastroenterology
|
2013
|
2.37
|
36
|
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.
|
J Hepatol
|
2008
|
2.22
|
37
|
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.
|
Gastroenterology
|
2013
|
2.21
|
38
|
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.
|
Gastroenterology
|
2013
|
2.13
|
39
|
Major achievements in hepatocellular carcinoma.
|
Lancet
|
2009
|
2.10
|
40
|
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
|
J Hepatol
|
2006
|
1.98
|
41
|
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.
|
Gastroenterology
|
2009
|
1.90
|
42
|
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
|
Annu Rev Med
|
2010
|
1.86
|
43
|
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.
|
Hepatology
|
2003
|
1.85
|
44
|
Chemoembolization for intermediate HCC: is there proof of survival benefit?
|
J Hepatol
|
2011
|
1.84
|
45
|
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.
|
Gastroenterology
|
2011
|
1.77
|
46
|
Staging systems in hepatocellular carcinoma.
|
HPB (Oxford)
|
2005
|
1.71
|
47
|
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.
|
Gastroenterology
|
2012
|
1.71
|
48
|
Cancer gene discovery in hepatocellular carcinoma.
|
J Hepatol
|
2010
|
1.68
|
49
|
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
|
J Hepatol
|
2010
|
1.66
|
50
|
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.
|
Liver Transpl
|
2004
|
1.65
|
51
|
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.
|
Hepatology
|
2004
|
1.65
|
52
|
Experimental models of hepatocellular carcinoma.
|
J Hepatol
|
2008
|
1.61
|
53
|
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
|
Nat Rev Gastroenterol Hepatol
|
2012
|
1.57
|
54
|
Pathogenesis of hepatocellular carcinoma and molecular therapies.
|
Curr Opin Gastroenterol
|
2009
|
1.52
|
55
|
New strategies in hepatocellular carcinoma: genomic prognostic markers.
|
Clin Cancer Res
|
2010
|
1.46
|
56
|
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
|
Clin Cancer Res
|
2012
|
1.44
|
57
|
Induction of hepatocellular carcinoma by in vivo gene targeting.
|
Proc Natl Acad Sci U S A
|
2012
|
1.31
|
58
|
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.
|
Curr Opin Oncol
|
2008
|
1.26
|
59
|
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
|
J Hepatol
|
2012
|
1.26
|
60
|
Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.
|
Gastroenterology
|
2013
|
1.26
|
61
|
Treatment of hepatocellular carcinoma: is there an optimal strategy?
|
Cancer Treat Rev
|
2003
|
1.25
|
62
|
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
|
Gastroenterology
|
2008
|
1.21
|
63
|
Molecular profiling to predict hepatocellular carcinoma outcome.
|
Expert Rev Gastroenterol Hepatol
|
2009
|
1.17
|
64
|
Hepatitis B virus and hepatocellular carcinoma.
|
J Hepatol
|
2003
|
1.14
|
65
|
HCC surveillance: who is the target population?
|
Hepatology
|
2003
|
1.12
|
66
|
Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.
|
Hepatology
|
2011
|
1.07
|
67
|
Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
|
Clin Cancer Res
|
2012
|
1.05
|
68
|
Molecular approaches to treatment of hepatocellular carcinoma.
|
Dig Liver Dis
|
2010
|
1.01
|
69
|
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
|
J Hepatol
|
2012
|
1.01
|
70
|
Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision.
|
Liver Transpl
|
2003
|
0.98
|
71
|
Two decades of advances in hepatocellular carcinoma research.
|
Semin Liver Dis
|
2010
|
0.94
|
72
|
Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.
|
Semin Liver Dis
|
2006
|
0.94
|
73
|
Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.
|
Cancer Cell
|
2010
|
0.92
|
74
|
Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study.
|
Hepatogastroenterology
|
2004
|
0.92
|
75
|
Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography.
|
Liver Transpl
|
2004
|
0.91
|
76
|
Prognostic assessment and evaluation of the benefits of treatment.
|
J Clin Gastroenterol
|
2002
|
0.90
|
77
|
Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.
|
Hepatology
|
2012
|
0.88
|
78
|
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
|
Nat Rev Clin Oncol
|
2015
|
0.88
|
79
|
p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma.
|
J Hepatol
|
2003
|
0.86
|
80
|
Hepatocellular carcinoma: a clinical update.
|
MedGenMed
|
2003
|
0.86
|
81
|
Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials.
|
J Hepatol
|
2008
|
0.85
|
82
|
Gene expression profiles in hepatocellular carcinoma: not yet there.
|
J Hepatol
|
2004
|
0.85
|
83
|
miRNA delivery: emerging therapy for hepatocellular carcinoma.
|
Gastroenterology
|
2010
|
0.84
|
84
|
[Diagnosis and treatment of hepatocellular carcinoma].
|
Med Clin (Barc)
|
2009
|
0.84
|
85
|
Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.
|
J Natl Cancer Inst
|
2008
|
0.83
|
86
|
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
|
J Clin Oncol
|
2009
|
0.83
|
87
|
Lymphotoxins: new targets for hepatocellular carcinoma.
|
Cancer Cell
|
2009
|
0.83
|
88
|
Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?
|
J Hepatol
|
2005
|
0.82
|
89
|
A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.
|
Hepatology
|
2011
|
0.82
|
90
|
Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma.
|
Hepatology
|
2012
|
0.82
|
91
|
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal.
|
Liver Transpl
|
2006
|
0.82
|
92
|
Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.
|
J Hepatol
|
2006
|
0.82
|
93
|
Liver transplantation in hepatocellular carcinoma.
|
Transpl Int
|
2005
|
0.81
|
94
|
Hepatocellular carcinoma enters the sequencing era.
|
Gastroenterology
|
2011
|
0.80
|
95
|
HCC Is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management.
|
Hepatology
|
2012
|
0.80
|
96
|
[Cell biology and genetics in liver cancer].
|
Gastroenterol Hepatol
|
2007
|
0.80
|
97
|
Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma.
|
Gastroenterology
|
2010
|
0.79
|
98
|
Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?
|
Clin Liver Dis
|
2005
|
0.79
|
99
|
Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma.
|
J Natl Cancer Inst
|
2011
|
0.79
|
100
|
Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation.
|
J Clin Ultrasound
|
2003
|
0.79
|
101
|
Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization.
|
Radiology
|
2004
|
0.77
|
102
|
Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps.
|
J Hepatol
|
2012
|
0.77
|
103
|
Expected developments in hepatology.
|
Best Pract Res Clin Gastroenterol
|
2002
|
0.77
|
104
|
Accomplishments in 2008 in the management of hepatobiliary cancers.
|
Gastrointest Cancer Res
|
2009
|
0.76
|
105
|
Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.
|
J Hepatol
|
2011
|
0.75
|
106
|
Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?
|
J Hepatol
|
2013
|
0.75
|
107
|
Applicability of adult-to-adult living donor liver transplantation.
|
J Hepatol
|
2005
|
0.75
|
108
|
microRNAs and the MYC network: a major piece in the puzzle of liver cancer.
|
Gastroenterology
|
2011
|
0.75
|
109
|
Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data.
|
Liver Transpl
|
2006
|
0.75
|
110
|
Sunitinib and the benefits of a negative study.
|
Lancet Oncol
|
2009
|
0.75
|
111
|
Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
|
Nature
|
2015
|
0.75
|